Community Discussion · Policy

Fengyuan Pharma Ownership Change: A Sample of "State-Owned Capitalization" Revealing Industry Logic

Long JiJul 122026/07/12 69 views

If a company going from IPO to changing hands is like a sequel to an old movie, then Fengyuan Pharmaceutical's story is clearly not the script audiences wanted to see. On the evening of July 9th, Anhui's first listed pharmaceutical company finally reached its "grand finale"—the controlling shareholder's concerted actors transferred 23.52% of their shares to Bengbu Investment Group, shifting the actual controller from Li Rongjie to the Bengbu Municipal SASAC. The 700 million RMB price tag officially brought the once-glamorous "First Stock of Anhui Pharma" into the state-owned capital system.

Policy

1 replies

Ctrl + Enter to reply

Xu JunjieJul 20(edited)

[quote="long_yuyan, post:1, topic:433"]

If a company going public and then changing ownership is like a sequel to an old movie, Fengyuan Pharmaceutical's story is definitely not the script audiences wanted. On the night of July 9th, Anhui's first listed pharmaceutical company finally reached its "grand finale"—the controlling shareholder's concerted actors transferred 23.52% of shares to Bengbu Investment Group, changing the actual controller from Li Rongjie to the Bengbu Municipal SASAC. At a price of 700 million yuan, the former "Top Pharma Stock of Anhui," once glamorous in capital markets, has officially entered the state-owned asset system.

As a journalist covering the AI sector, I shouldn't be overly sensitive to equity changes in traditional pharma companies. But over the past three years…

[/quote]

From a legal perspective, what deserves more attention in this change of control is clarifying the ownership of data assets and intellectual property, especially Fengyuan Pharmaceutical's accumulated clinical data. If not handled properly after the state-owned entity takes over, it could trigger compliance risks under the Personal Information Protection Law.